HOME >> BIOLOGY >> NEWS
Hypothermia helps brain heal after cardiac arrest, finds University of Pittsburgh study

BOSTON, May 30 Cooling body temperature to levels consistent with hypothermia improves survival when induced after cardiac arrest and also promotes growth factors important for the brains recovery, suggests a study performed by researchers in the department of emergency medicine at the University of Pittsburgh School of Medicine. Preliminary results of their study were reported today at the 2003 Annual Meeting of the Society of Academic Emergency Medicine (SAEM) in Boston.

Although the study involved animals, the findings already had an influence on the management of cardiac arrest patients being treated at the University of Pittsburgh Medical Center (UPMC), where the lead researcher is also a practicing emergency medicine physician.

Cardiac arrest is the sudden, abrupt loss of heart function. Death usually occurs within minutes unless cardiopulmonary resuscitation (CPR) and rapid defibrillation is available. As cardiac arrest progresses, blood flow to the brain ceases. If a patient survives long enough to make it to the hospital, the patient often will be in a coma and at risk of permanent brain injury. In fact, less than 10 percent of patients make it through the chain-of-survival (early access to care, early CPR, early defibrillation and early advanced care). The Pitt researchers sought to find out if hypothermia treatment played a role in survival from cardiac arrest and brain recovery.

In animal studies, the researchers found that when the animals were cooled to 33 degrees Celsius (91.4 degrees Fahrenheit) beginning one hour after cardiac arrest, there was 100 percent survival, whereas 75 percent of the animals left at normal temperature of 37C (98.6F) survived. Furthermore, microscopic brain injury was reduced by half, and some animals showed functional improvement in as little as 12 hours after cardiac arrest was induced. Conversely, the animals left at normal temperature after cardiac arrest showed little or no functional improveme
'"/>

Contact: Maureen McGaffin
412-647-3555
University of Pittsburgh Medical Center
30-May-2003


Page: 1 2

Related biology news :

1. Atacama rover helps NASA learn to search for life on Mars
2. Reducing allergens in the home helps inner-city children with asthma
3. As informatics grows, Indiana University helps set research agenda
4. New diagnostic technology helps justify earlier cataract surgery
5. New technique helps scientists reveal interactions between genes and drugs
6. Living at home helps young mothers stay in school
7. Hormone helps fish to mate, may affect human hearing
8. Harmless virus helps slow HIV by boosting immune proteins
9. Study helps explain island populations susceptibility to exotic diseases
10. Utah scientist helps discover new mouse species -- and maybe a new genus
11. Choice of food helps hungry caterpillar

Post Your Comments:
(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce ... Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center ... come from and how agriculture impacts their daily lives. This unique exhibit also features ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: